Revision summary
DBT, public labs, BIRAC, a large patient market, and generics plants explain India’s biotech bustle. Farm tools and contract research add demand besides hospitals. Biopharma gained vaccines, biosimilars, recombinant insulin, and diagnostics, including UN-prequalified shots. Gaps are original discovery, trial capital, and slow or split regulation. Policy should keep cheap quality biologics and add a cleaner, faster regulatory clock.
Model answer
Copper italics in this answer — like this — are the key facts. Each one is unpacked in the Facts & figures rail.
Introduction
Biotechnology uses living cells and tools of genetics to make drugs, seeds, enzymes, and diagnostics. India is busy in this field because it has low-cost scientific labour, a large patient and farm market, public labs, and a generics industry that can absorb new tools. Biopharma—vaccines, biosimilars, insulin, and diagnostics—has been the clearest commercial winner, though regulation and original discovery still lag.
Body
Why so much biotech activity
- Department of Biotechnology (DBT) (1986), CSIR labs, ICAR, and IITs built a public pipeline of skills; BIRAC later funded start-ups and industry–academia projects.
- A huge disease burden (vaccines, TB, diabetes, cancer biosimilars) and a huge agri-base (tissue culture, biofertilisers, Bt cotton) create domestic demand.
- English-speaking scientists, IT-enabled trial data, and contract research attract global firms to Indian labs and plants.
- Patent law after TRIPS pushed firms from only copying small-molecule drugs toward process skill, biosimilars, and vaccines where India could still compete.
- Start-up policy, biotech parks, and export of bulk enzymes and reagents added a private layer on the old public-lab base.
- Activity is also high because the problems are public: cattle vaccines, diagnostics for outbreaks, and seed stress under climate change cannot wait for imported kits alone.
Benefits to biopharma
- India is a major supplier of vaccines (including WHO-prequalified products for UN agencies): pentavalent, hepatitis B, rotavirus, and later other public-programme shots built on this base.
- Biosimilars of monoclonal antibodies and other biologics, plus recombinant insulin, cut treatment cost in India and in other developing markets compared with originator brands.
- Diagnostics (ELISA, molecular kits, later point-of-care) grew from the same skill set that serves hospitals and the ICMR network.
- Contract manufacturing and research for global pharma brought GMP plants, cold-chain discipline, and jobs in Hyderabad, Pune, Bengaluru, and Ahmedabad belts.
- Public programmes (universal immunisation, later Mission Indradhanush) gave a volume market that private biopharma could plan around.
- The sector still leans more on follow-on biologics and vaccines than on first-in-class molecules; that is a real benefit for access, not yet a Nobel-pipeline story.
Gaps
- Regulatory delay and overlapping DBT–CDSCO–GEAC lanes slow trials and GM as well as novel biologics.
- Venture capital, animal-house, and Phase-III capacity remain thinner than China’s or the US scale.
- Bt cotton showed farm biotech can spread fast; food GM remains politically stuck, which splits the sector’s energy.
- Data integrity and quality scares in some plants can stain the whole export brand.
Way forward
- One predictable regulator clock for clinical trials and biosimilar pathways, with world-class inspection rather than extra paper.
- Public purchase that rewards quality and new antigens, not only the lowest bid that kills R&D.
- BIRAC-scale funding for translational labs, cluster freeze-dry and fill-finish, and skill in bioprocess engineering.
- Open biopharma to ethical data-sharing for rare diseases while protecting privacy.
- Keep access as the Indian edge: cheap, good-enough biologics for the South, while a few centres chase original discovery.
Flow diagram
flowchart TD DR[Disease farm market] --> BT[Biotech activity] PUB[DBT BIRAC CSIR] --> BT GEN[Generics GMP skill] --> BT BT --> V[Vaccines biosimilars insulin kits] V --> ACC[Lower cost public programmes] REG[Faster quality regulation] --> V
Conclusion
Biotechnology is busy in India because public science, a huge health and farm market, and a generics culture met global contract demand. Biopharma gained vaccines, biosimilars, insulin, and diagnostics that cut cost and serve immunisation. The next gain is faster clean regulation and more original biologics, without losing the access model.
Quick related
Students also ask
-
Among several factors for India's potential growth, savings rate is the most effective one. Do you agree? What are the other factors available for growth potential?
Next question on this syllabus topic (2017 · Q1). View answer →
-
Is Indian biotech only about GM food?
No. Vaccines, biosimilars, diagnostics, enzymes, and tissue culture are larger in jobs and exports than food GM, which remains limited.
-
Did biopharma only copy foreign drugs?
Much of the gain is process skill, vaccines, and biosimilars. That still lowered prices. First-in-class discovery is the unfinished part.
Same topic · past papers
UPSC has asked this before
These previous-year questions sit on the same topic. Open one to practise the earlier ask.
More from this topic
Q17 · UPSC Mains 2026 · GS III · 15 marks · Solution
What are the challenges to solid waste management in India? Discuss the governmental policy framework on solid waste management. Discuss the success/failure cases of Delhi and Indore cities highlighting the salient features of their solid waste management initiatives.
Indian Economy
• Rapid urbanization has made solid waste management a critical environmental and public health crisis in India. • Key challenges include lack of source segregation, inadequate processing infrastructure, reliance on unprotected informal workers, and financially weak urban local bodies. • The policy framework relies on the SWM Rules 2016, Swachh Bharat Mission (Urban), and Plastic Waste Management Rules 2016. • Indore succeeded through 100% source segregation, zero dump-site remediation, and strict enforcement with digital monitoring. • Delhi failed due to overloaded legacy landfills (Ghazipur, Bhalswa), lack of decentralization, and fragmented municipal governance. • A successful transition requires moving to a circular economy focused on source segregation, decentralized processing, and polluter accountability.
Q16 · UPSC Mains 2026 · GS III · 15 marks · Solution
What is Agentic Artificial Intelligence (AI)? Explain its working. Describe its applications with suitable examples. Discuss the advantages, risks and challenges associated with agentic AI systems.
Indian Economy
Agentic Artificial Intelligence represents an advanced paradigm where AI systems operate with autonomy, setting goals and executing complex workflows without constant human prompts. Unlike traditional generative AI that merely responds to queries, agentic AI uses perception, planning, memory, and tool-use to achieve multi-step objectives. Its applications span across autonomous software engineering, supply chain optimization, and automated financial trading. While offering massive productivity gains and dynamic problem-solving, these systems pose significant risks including lack of transparency, alignment failures, security vulnerabilities, and ethical dilemmas. Governance frameworks and robust guardrails are essential to harness their potential safely.
Q15 · UPSC Mains 2026 · GS III · 15 marks · Solution
Mention salient features of 'Mission Drishti'. Discuss the imaging techniques used in the satellite launched on 3rd May 2026. Why is it being considered world's first satellite of its kind?
Indian Economy
Mission Drishti represents a major leap in India's space-based Earth observation capabilities, launched on 3rd May 2026. The mission employs advanced multi-spectral and hyperspectral imaging techniques to capture high-resolution data across various atmospheric and terrestrial layers. It is hailed as a global first due to its unique integration of real-time onboard edge computing with quantum encryption for secure data transmission. The satellite significantly enhances resource management, disaster response, and strategic surveillance. It aligns with India's policy of leveraging space technology for sustainable development and national security.